| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Approval Decision example | NDA | — | Subscribe to access the data. | Small Molecules | Hematologic System | ||
Approval Decision example | NDA | — | Subscribe to access the data. | Small Molecules | Hematologic System | ||
Approval Decision example | NDA | — | Subscribe to access the data. | Small Molecules | Hematologic System |
Recent Updates
Recently added Catalysts
Takeda Pharmaceutical Company Limited$16.56
-0.05 (-0.3%)
A 86Pipeline Score Undervalued Pharma · Commercial
Market Cap
50.93 B
EPS
0.41
P/E Ratio
40.07 $
Value Trade
56.53 M
-2.64 %
Week
-3.16 %
1 Month
-12.68 %
3 Month
15.25 %
6 Month
-6.88 %
5 Year
-40.59 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
1.50 M
52 Week Range
12.99 - 18.90
% held by Insiders
0 %
% held by Institutions
3.12 %
Enterprise Value
77.88 B
Total Shares
3.16 B
Short %
0.17 %
Float Shares
3.16 B
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Takeda Pharmaceutical Company Limited
79Total events
9Upcoming
48Tier-1 (high impact)
2022 – 2027Coverage
Upcoming catalysts 9
Event history 70
Q3 2026
Jul 2026
●Trial CompletionZasocitinibTrial
Head-to-head Phase III trial vs Sotyktu expected to complete in July 2026
moderate to severe plaque psoriasissource ↗
Jun 24, 2026
◆Management ChangeCorporate
Appointment of Julie Kim as Representative Director, President and CEO
Jun 15, 2026
▲Full ResultsTAK-861Clinical Data
Pivotal study data show Oveporexton improved daily function, cognition and nighttime sleep
Narcolepsy Type 1source ↗
Jun 11, 2026
▲Topline ReadoutZasocitinibClinical Data
Zasocitinib significantly outperforms deucravacitinib in head-to-head Phase 3 psoriasis study
psoriasissource ↗
Jun 9, 2026
●sBLA SubmissionENTYVIORegulatory Filing
U.S. FDA accepts supplemental Biologics License Application for intravenous ENTYVIO in pediatric UC and CD
pediatric ulcerative colitis and Crohn's diseasesource ↗
Jun 2026
◆PDUFA DateicotrokinraRegulatory Filing
PDUFA decision expected for icotrokinra
plaque psoriasissource ↗
May 19, 2026
▼Restructuring LayoffsCorporate
Takeda announces layoff of about 4,500 employees in fiscal year 2026 as part of transformation program
May 6, 2026
Drug Pipeline Intelligence
A86
Pipeline Score $180.4B
Pipeline ValueUndervalued
Valuation Signal307
Drugs Scored11.8x
rNPV / MCap Top 98%
Large Pharma (rank 19 of 911)
Percentile RankTakeda Pharmaceutical Company Limited earns an A-grade pipeline score (86/100), with $181.0B risk-adjusted pipeline value, led by Peginesatide in Chronic Kidney Disease (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Peginesatide Small molecule | Chronic Kidney Disease | Phase 3 | NCT01478971 | 68% | $16.8B | COMPLETED | 184 | - | - | Feb 1, 2013 | - | Sep 20, 2016 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
TAK-881 | primary immunodeficiency disease | Phase 2/3 | 2026-05-06 | comparable pharmacokinetics between TAK-881 and HYQVIA | Riassunto: Takeda annuncia i risultati principali positivi dallo studio clinico pivotale di fase 2/3 su TAK-881 nella malattia da immunodeficienza primaria (IDP) Read More | |
TAK-881 | primary immunodeficiency disease | Phase 2/3 | 2026-05-06 | comparable pharmacokinetics between TAK-881 and HYQVIA | Riassunto: Takeda annuncia i risultati principali positivi dallo studio clinico pivotale di fase 2/3 su TAK-881 nella malattia da immunodeficienza primaria (IDP) Read More | |
TAK-881 | primary immunodeficiency disease | Phase 2/3 | 2026-05-06 | comparable pharmacokinetics between TAK-881 and HYQVIA | Riassunto: Takeda annuncia i risultati principali positivi dallo studio clinico pivotale di fase 2/3 su TAK-881 nella malattia da immunodeficienza primaria (IDP) Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TAK
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TAK Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TAKTakeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO
Takeda has announced new assignments of directors, including the appointment of Julie Kim as the Representative Director, President, and CEO. This leadership change is part of the company's ongoing strategy to enhance its governance and operational effectiveness. The announcement reflects Takeda's commitment to strong leadership in the biopharma sector.
Read more →TAKNew Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1
Takeda's new pivotal study data reveals that Oveporexton significantly enhances daily function, cognition, and nighttime sleep quality in individuals with Narcolepsy Type 1. These findings suggest a promising advancement in treatment options for this condition, potentially improving the quality of life for affected patients.
Read more →TAKTakeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
Takeda's Zasocitinib has demonstrated significant efficacy in a Phase 3 study, outperforming Deucravacitinib in treating psoriasis. This promising result may redefine expectations for oral treatments in this indication. The findings suggest that Zasocitinib could become a leading option for patients seeking effective psoriasis management.
Read more →TAKU.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
Takeda's application for intravenous ENTYVIO® (vedolizumab) has been accepted by the U.S. FDA for the treatment of pediatric patients with ulcerative colitis and Crohn's disease. This acceptance marks a crucial step in expanding treatment options for children suffering from these conditions. ENTYVIO® is already approved for adult patients, and this development could enhance its accessibility to younger patients.
Read more →TAKNet Debt and Adjusted Net Debt Takeda defines Net Debt as the book value of bonds and loans on consolidated statements of financial position adjusted only for cash and cash equivalents and Adjusted Net Debt first by calc
Takeda has released detailed explanations of its financial measures, particularly focusing on Non-IFRS metrics, such as Core Revenue and Adjusted Free Cash Flow. These measures aim to provide clarity on the company's operations by excluding non-recurring items and those unrelated to its core performance. However, the complexity and new terminology introduced may challenge investors' understanding and impede cross-comparisons with other firms in the industry. The company emphasizes the use of these metrics for internal evaluation and planning while cautioning that they should not be viewed in isolation from standard IFRS measures.
Read more →TAKTakeda cuts send layoffs soaring in May, rising year over year
Takeda has announced significant layoffs, cutting approximately 4,500 employees as part of a cost-cutting transformation program. This decision contributes to a record number of layoffs in the biopharma sector for May 2026, with a year-over-year increase in job cuts. Despite the layoffs, Takeda is also hiring for new roles to support future growth.
Read more →TAKTakeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
Takeda has announced its full year results for FY2025 and provided an outlook for FY2026. The report highlights progress in its pipeline, although specific details about the results and outlook are not included in the provided text.
Read more →TAKFINANCIAL APPENDIX Definition of Non-IFRS Measures Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations A- 1 Reconciliations and Other Financial Information FY2025 Reported Results wit
The article provides a detailed account of Takeda's non-IFRS financial measures, including definitions, reconciliations, and adjustments for financial reporting. It emphasizes the importance of Core Financial Measures, such as Core Revenue and Core Operating Profit, and their role in evaluating the company's underlying business performance. Additionally, the article discusses how Constant Exchange Rate (CER) adjustments provide insight into financial results unaffected by currency fluctuations. Overall, it serves as a comprehensive guide for understanding Takeda's financial strategy and reporting metrics for FY2025.
Read more →TAK武田薬品、原発性免疫不全症（PID）を対象としたTAK-881の主要第2/3相臨床試験で良好なトップライン結果を発表
The article discusses the results of a Phase 2/3 trial for TAK-881, a treatment for primary immunodeficiency disease (PID). The trial reportedly yielded favorable outcomes, although specific details are not provided. The focus is on the effectiveness of TAK-881 in addressing PID symptoms.
Read more →TAKIncreased capital boosts biotech R&D job postings, employment
The biotech R&D job market is experiencing significant growth, with job postings increasing by 21% year-over-year as of April. Employment in the sector reached a record high in Q1, driven by an improving capital environment and increased follow-on offerings. Major companies are actively hiring, indicating a positive trend for biotech professionals seeking opportunities.
Read more →TAKTakeda anuncia resultados positivos de primeira linha do estudo clínico pivotal de Fase 2/3 do TAK-881 em Imunodeficiência Primária (IDP)
Takeda announced positive results from its pivotal Phase 2/3 study of TAK-881 for Primary Immunodeficiency (PID). The study demonstrated comparable pharmacokinetics between TAK-881 and the established treatment HYQVIA. TAK-881 showed effective immune protection and a favorable safety profile, potentially allowing for reduced infusion volume and frequency. Takeda plans to submit regulatory approvals for TAK-881 by fiscal year 2026.
Read more →TAKTakeda presenta resultados positivos preliminares del ensayo pivotal de fase 2/3 de TAK-881 en inmunodeficiencia primaria (IDP)
Takeda announced positive preliminary results from the pivotal phase 2/3 study of TAK-881 for primary immunodeficiency (IDP). The study met its primary endpoint, showing pharmacokinetic comparability to HYQVIA. Secondary endpoints indicated that TAK-881 had comparable safety and efficacy profiles. The results suggest that TAK-881 could improve treatment flexibility and patient experience.
Read more →TAKTakeda gibt positive Topline-Ergebnisse einer entscheidenden klinischen Phase-2/3-Studie mit TAK-881 bei primären Immundefekten (PID) bekannt
Takeda announced positive topline results from the TAK-881-3001 Phase 2/3 clinical trial for primary immunodeficiencies (PID). The study achieved its primary endpoint, showing pharmacokinetic comparability between TAK-881 and HYQVIA. Secondary endpoints indicated similar safety and efficacy profiles, with TAK-881 potentially offering a reduced immunoglobulin dose and shorter infusion times. Further results are expected at an upcoming medical forum.
Read more →TAKTakeda annonce les premiers résultats positifs d’un essai clinique pivot de phase 2/3 sur le TAK-881 dans le traitement des déficits immunitaires primaires (DIP)
Takeda announced positive results from its pivotal Phase 2/3 trial of TAK-881 for primary immunodeficiency disorders (PID). The trial met its primary endpoint, showing comparable pharmacokinetics between TAK-881 and the established treatment HYQVIA. Secondary endpoints also indicated similar safety and efficacy profiles, suggesting that TAK-881 could improve patient experience with less frequent infusions.
Read more →TAKSamenvatting: Takeda maakt positieve voorlopige resultaten bekend van een cruciaal fase 2/3-klinisch onderzoek naar TAK-881 bij primaire immuundeficiëntie (PID)
Takeda announced positive preliminary results from the TAK-881-3001 Phase 2/3 clinical trial for patients with primary immunodeficiency (PID). The study demonstrated that TAK-881, a subcutaneously administered immunoglobulin, met its primary endpoint and showed comparable pharmacokinetics to HYQVIA. Additionally, secondary endpoints indicated similar safety and efficacy profiles between the two treatments.
Read more →TAKRiassunto: Takeda annuncia i risultati principali positivi dallo studio clinico pivotale di fase 2/3 su TAK-881 nella malattia da immunodeficienza primaria (IDP)
Takeda has announced positive results from its pivotal Phase 2/3 study of TAK-881 for primary immunodeficiency disease (PID). The study met its primary endpoint, showing comparable pharmacokinetics between TAK-881 and the market-established HYQVIA. Additionally, secondary endpoints indicated similar safety and efficacy profiles for both treatments.
Read more →TAKTakeda宣布針對原發性免疫缺陷病（PID）開發的新藥TAK-881在二/三期臨床試驗中取得正面頂線結果
Takeda announced positive results from the Phase 2/3 trial of TAK-881 for primary immunodeficiency (PID). The drug demonstrated significant efficacy and a favorable safety profile compared to existing treatments. TAK-881 offers a more convenient dosing schedule, potentially improving patient adherence. Further studies are planned to confirm these findings and assess long-term outcomes.
Read more →TAKTakeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
Takeda announced positive topline results from the pivotal Phase 2/3 trial of TAK-881 for Primary Immunodeficiency Disease (PID). The trial showed that TAK-881 is pharmacokinetically comparable to HYQVIA, with similar safety and efficacy profiles. The findings suggest that TAK-881 could reduce infusion volume and duration, potentially improving patient experience. Takeda plans to submit applications for regulatory approval in fiscal year 2026.
Read more →TAKBiopharmas pull back on layoffs in Q1
In Q1 2026, biopharma layoffs slowed significantly, with only 35 companies making cuts compared to 74 in Q1 2025. Despite the decrease in companies laying off employees, the total number of affected workers increased to 6,593, largely due to Viatris's planned reductions. Optimism is noted in funding, with seven biopharmas going public, and hiring activity gaining momentum towards the end of the quarter.
Read more →TAKTakeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
Takeda announced promising results from Phase 3 studies of zasocitinib, a selective oral TYK2 inhibitor for moderate-to-severe plaque psoriasis. The studies demonstrated that over half of the patients achieved clear or almost clear skin at week 16, with rapid responses noted as early as week 4. Zasocitinib maintained a favorable safety profile, supporting its potential as a leading oral treatment option.
Read more →TAK11 Companies Hiring Now in New York
The job market for life sciences in New York is thriving, with a 22% increase in job postings year over year. Major companies like AbbVie, Amgen, and Takeda are among those hiring, offering a variety of positions across the state. The growing demand for talent reflects the robust life sciences sector in the region.
Read more →TAKThe Next Cambridge? LA Sets Its Sights Higher
The Los Angeles region is emerging as a significant player in California's life sciences sector, with over 3,000 companies and a $58 billion annual economic output. In 2024, the region attracted $4.4 billion in venture capital, signaling increased investor confidence. Despite challenges like fragmentation and complexity, initiatives are underway to establish LA as a global life sciences hub.
Read more →TAKTakeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
Takeda and Protagonist Therapeutics announced that the FDA has accepted the New Drug Application for rusfertide, a first-in-class therapy for polycythemia vera. The drug has been granted Priority Review and has received several designations aimed at expediting its development. Clinical trials have shown rusfertide to be effective in controlling hematocrit levels and improving patient-reported outcomes.
Read more →TAKAlan Walshe Appointed General Manager of Takeda Canada
Takeda Canada has appointed Alan Walshe as General Manager, bringing 17 years of experience with the company. His leadership is expected to enhance the company's growth and impact in Canada, focusing on innovative therapies and patient access. Walshe expressed confidence in advancing Takeda's mission in this key market.
Read more →TAK9 Companies Hiring in Boston
Despite a 25% drop in job postings year over year in January, Boston continues to be a key player in the life sciences sector. Major companies such as Vertex Pharmaceuticals, Foundation Medicine, Eli Lilly, and Takeda are actively hiring. This indicates ongoing opportunities in the biotech and pharmaceutical industries in the city.
Read more →TAKU.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
Takeda's New Drug Application for oveporexton (TAK-861) has been accepted by the FDA, which has granted it Priority Review for treating narcolepsy type 1. Oveporexton is designed to restore orexin signaling, addressing the underlying deficiency in patients. The FDA has set a PDUFA goal date for the third quarter of this year, marking a potential breakthrough in treatment options for this condition.
Read more →TAKFRUZAQLA(TM) (fruquintinib capsules) now reimbursed in Ontario to treat metastatic colorectal cancer (mCRC)
Takeda Canada has announced that Fruzaqla (fruquintinib capsules) is now included in Ontario's Exceptional Access Program for reimbursement. This treatment is aimed at adult patients with metastatic colorectal cancer (mCRC) who have not responded to standard therapies. The authorization follows positive results from Phase 3 trials demonstrating improved survival rates. Takeda is committed to ensuring access for all eligible patients across Canada.
Read more →TAKTakeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead
Takeda reported its third-quarter results for FY2025, highlighting a narrowing gap between Growth & Launch Products revenue and VYVANSE erosion. The company raised its forecasts due to operational efficiencies and foreign exchange benefits. Takeda is on track to launch three transformative products within 18 months, aiming to redefine care standards and enhance shareholder value.
Read more →TAK10 Companies Hiring IT Professionals Now
The article highlights the growing demand for IT professionals in the biopharma sector, noting an increase in job postings towards the end of 2025. Despite a midyear decline, the final months of the year saw a resurgence, with December's job totals closely aligning with the previous year. January 2026 has also shown a positive trend in job openings.
Read more →TAKFINANCIAL APPENDIX Definition of Non-IFRS Measures Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations A- 1 Reconciliations and Other Financial Information FY2025 Q3 YTD Reported Resu
The article provides a detailed explanation of Takeda's non-IFRS financial measures, emphasizing their utility in understanding core business performance and financial trends. It discusses how adjustments are made to exclude items not related to ongoing operations, alongside the definition of constant exchange rate (CER) changes. The report also outlines practices around free cash flow and adjusted free cash flow, signifying their importance in evaluating the company's liquidity and strategic financial decisions. The limitations of these presentations are also addressed, noting challenges in comparability among industry peers.
Read more →TAKTakeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
Takeda has announced the U.S. availability of GAMMAGARD LIQUID ERC, a ready-to-use liquid immunoglobulin therapy designed for patients with primary immunodeficiency. This therapy features a low IgA content and does not require reconstitution, making it easier to administer. It is available in two vial sizes and can be stored at room temperature for extended periods. However, it carries warnings for potential severe hypersensitivity reactions.
Read more →TAK12 Companies Hiring R&D Professionals Now
The article highlights the resurgence of research and development job postings in the biopharma sector, following a decline. It notes that employed and unemployed professionals are primarily targeting these roles. The piece lists 12 companies currently hiring for R&D positions, indicating a positive trend in the job market.
Read more →TAKJPM26: Protagonist Has a $400M Decision To Make. It’s a No-Brainer
Protagonist CEO Dinesh Patel is considering whether to opt out of a co-development deal with Takeda for the drug rusfertide, which targets rare blood cancer. Opting out could yield Protagonist $400 million and allow it to concentrate on its own drug pipeline. The successful Phase III trial results for rusfertide have increased optimism about its market potential, with the FDA's priority review expected to expedite its approval.
Read more →TAK11 Companies Hiring Manufacturing Professionals Now
As 2026 begins, major pharmaceutical companies are ramping up investments in manufacturing, leading to a surge in job opportunities. With many firms onshoring their manufacturing operations, there are numerous roles available for those seeking employment in this sector. The article highlights 11 companies currently hiring in manufacturing.
Read more →TAKTakeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
Takeda and Protagonist Therapeutics have submitted a New Drug Application (NDA) to the FDA for rusfertide, aimed at treating polycythemia vera (PV). This investigational drug is designed to regulate iron homeostasis and red blood cell production. The NDA follows positive results from the Phase 3 VERIFY study, which demonstrated rusfertide's efficacy in controlling hematocrit levels and reducing the need for phlebotomy.
Read more →TAKTakeda’s Commitment to Trial Representation is Shaping the Future of Clinical Research
Takeda is enhancing clinical trial representation under the leadership of Angel Akinbinu. Her personal experiences with healthcare disparities fuel the company's commitment to diversity and inclusion in clinical research. The team aims to educate and connect diverse patient populations with clinical trial opportunities, ensuring that research reflects the broader community. Takeda's values of integrity and fairness guide their efforts in this important area.
Read more →TAKTakeda’s $4B Nimbus Bet Pays Off With ‘Best-in-Class’ Phase III Plaque Psoriasis Data
Takeda's oral drug candidate, zasocitinib, has shown significant efficacy in two Phase III studies for plaque psoriasis, positioning the company to compete with Bristol Myers Squibb. Analysts predict the oral psoriasis market will exceed $5 billion by 2030, and Takeda plans to file a new drug application in early 2026. Despite limited data, the results suggest a strong potential for zasocitinib to redefine treatment options in this area.
Read more →TAKJapanese Pharmas Looking Beyond Borders for M&A to US, EU
Japanese pharmaceutical companies are shifting towards mergers and acquisitions, previously dominated by U.S. firms. Companies like Daiichi Sankyo and Otsuka are actively seeking global partnerships, particularly in oncology and nervous system disorders. This trend marks a significant change from their traditional focus on domestic growth, driven by a stagnant local market and the need for innovation.
Read more →TAKFDA Probing Patient Death Linked to Takeda’s Enzyme Replacement Therapy
The FDA is investigating adverse events related to Takeda's enzyme replacement therapy, Adzynma, following a patient death. This incident involved a pediatric patient with congenital thrombotic thrombocytopenic purpura (cTTP) who developed neurological symptoms and anti-ADAMTS13 antibodies after treatment. The investigation highlights concerns over antibody production that were not observed during clinical trials.
Read more →TAKThe Top 12 Companies Hiring in Biopharma Now
In November, biopharma job postings increased by 16% compared to October, signaling a potential recovery in hiring trends. However, there is still a year-on-year decrease of 17% compared to November 2024. The article lists the top 12 biopharma companies currently hiring, offering insights for job seekers in the industry.
Read more →TAKBioSpace2026 Best Places to Work Spotlights Most Desirable Workplaces
AbbVie and BridgeBio have been named the top large and small employers, respectively, in the BioSpace2026 Best Places to Work list, based on feedback from over 7,600 life sciences professionals. The list highlights 50 companies that excel in various workplace attributes, including innovation, culture, and career growth opportunities. AbbVie and Amneal Pharmaceuticals also received praise for their strong company cultures and commitment to employee engagement.
Read more →TAKFINANCIAL APPENDIX Definition of Non-IFRS Measures Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations A- 1 Reconciliations and Other Financial Information FY2025 H1 Reported Results
The article provides an in-depth overview of Takeda's financial reporting measures, specifically focusing on Non-IFRS measures and their definitions. It outlines the company's Core Financial Measures, including Core Revenue, Core Operating Profit, and Adjusted Free Cash Flow, which aim to present a clearer understanding of Takeda's operational performance by excluding certain items. The article further explains the concept of Constant Exchange Rate (CER) Change, which allows for year-over-year comparisons free from the effects of currency fluctuations. Overall, it serves as a financial appendix detailing important financial statistics and reconciliations for FY2025.
Read more →TAK8 Companies Hiring Now in Regulatory
The article discusses the current job market for regulatory positions in biopharma, highlighting that these roles provide job security amidst ongoing changes at the FDA. Demand for regulatory professionals is increasing, despite a slight year-over-year decline in job postings. Eight companies are noted for their open regulatory positions.
Read more →TAKTakeda Bets up to $11.4B for Up To Three Innovent Cancer Assets
Takeda has committed over $11 billion to partner with Innovent on three cancer therapies. This includes a $1.2 billion upfront payment for co-development rights to IBI363 and IBI343, both targeting solid tumors. If successful, the total deal could reach $11.4 billion, reflecting the potential of these next-generation treatments.
Read more →TAKQ3 Earnings Are Here, Novo Ditches Cell Therapy but Buys Akero, Gov’t Shutdown Hits CDC
Novo Nordisk has made significant moves in Q3, including acquiring Akero for $5.2 billion and discontinuing its cell therapy program. Takeda has also exited the cell therapy market. Meanwhile, the government shutdown is impacting the CDC, while the FDA continues to function normally with an average approval rate. The BIOSECURE Act has been reintroduced in a revised form.
Read more →TAKTakeda Makes $1B+ AI Bet With Nabla to Build Out Early Pipeline
Takeda has entered a multi-year AI partnership with Nabla Bio to enhance its early-stage pipeline after exiting cell therapy. The deal could exceed $1 billion, focusing on the design of antibodies and custom therapeutics. This strategic move follows a broader realignment aimed at improving company margins, which includes job cuts.
Read more →TAK9 Companies Hiring in Oncology
The article highlights the growing opportunities in the oncology sector for biopharma job seekers. With the global oncology market expected to nearly double by 2034, professionals can find job security in this field. Bryan Blair from GQR emphasizes the stability of oncology roles, suggesting they are a safe bet for career growth.
Read more →TAK▼ -5%on this news
FINANCIAL APPENDIX Definition of Non-IFRS Measures Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations A- 1 Reconciliations and Other Financial Information FY2025 Q1 Reported Results
Takeda has released its financial appendix that includes the definition and explanation of non-IFRS measures along with its FY2025 Q1 financial results. The document outlines the company’s core financial measures, including adjusted figures that exclude non-recurring items to aid investor understanding. It also explains how Takeda calculates metrics like Free Cash Flow and Adjusted Free Cash Flow, emphasizing their relevance in evaluating liquidity and business performance. The report highlights the significance of constant exchange rate changes for accurate year-over-year comparisons without the influence of exchange rate fluctuations.
Read more →TAK▼ -5.2%on this news
FINANCIAL APPENDIX Definition of Non-IFRS Measures Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations A- 1 Reconciliations and Other Financial Information FY2024 Reported Results wit
The article provides a comprehensive overview of Takeda's financial reporting, detailing the definitions and explanations of various Non-IFRS measures. It includes reconciliations of reported to core results for FY2024 and FY2025 forecasts, along with key metrics such as Core Revenue and Adjusted Free Cash Flow. These financial measures aim to assist investors and stakeholders in understanding Takeda's core business performance, excluding certain items deemed unrelated. There is a focus on Constant Exchange Rate (CER) changes and their impact on financial results.
Read more →TAKFINANCIAL APPENDIX Definition of Non-IFRS Measures Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations A- 1 Reconciliations and Other Financial Information FY2024 Q3 YTD Reported Resu
Takeda has released its financial appendix for FY2024 Q3, detailing Non-IFRS measures and a comprehensive overview of the reported financial results. The document includes reconciliations and information on adjusted free cash flow, net debt, and core financial metrics. The company emphasizes the importance of these core measures for investors, particularly in understanding underlying business performance free from non-recurring items. Additionally, Takeda has highlighted its approach to presenting constant exchange rate changes as it relates to year-over-year financial comparisons.
Read more →TAKReason for Submitting the Extraordinary Report The Company has submitted the Extraordinary Report pursuant to Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Law and Article 19, Paragraph 2, Item 3 of
Takeda Pharmaceutical Company Limited has submitted an Extraordinary Report regarding the dissolution of its subsidiary, Shire Pharmaceuticals International Unlimited Company, as part of a merger restructuring. This decision, resolved on September 25, 2024, will result in Shire being liquidated. The company will initiate the administrative and legal processes for liquidation in compliance with local regulations, although a completion date remains unknown. This merger and subsequent dissolution represent significant changes within Takeda's structure.
Read more →TAKFINANCIAL APPENDIX Definition of Non-IFRS Measures Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations A- 1 Reconciliations and Other Financial Information FY2024 H1 Reported Results
Takeda's FY2024 financial report includes definitions and explanations of non-IFRS measures, adjusting results to reflect operational performance without impacts from divestments and other non-recurring items. The company outlines its core financial measures, including core revenue and operating profit, and provides reconciliations between reported and core results. The report also discusses constant exchange rate changes and their relevance in evaluating business performance across fiscal years. Additionally, Takeda highlights its free cash flow metrics, emphasizing their significance for understanding liquidity and funding of strategic initiatives.
Read more →TAKFINANCIAL APPENDIX Definition of Non-IFRS Measures Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations A- 1 Reconciliations and Other Financial Information FY2024 Q1 Reported Results
Takeda has released its FY2024 Q1 financial results, detailing various non-IFRS measures and reconciling reported results with core financial metrics. The company emphasizes the significance of its Core Financial Measures for evaluating business performance. The presentation includes anticipated changes in financial reporting, particularly regarding foreign exchange rate impacts. The report aims to provide clarity for investors despite the complexity of the terminology used.
Read more →TAKFINANCIAL APPENDIX Definition of Non-IFRS Measures Definition of Core Financial Measures, Constant Exchange Rate Change, Free Cash Flow, and U.S. Dollar Convenience Translations A- 1 Definition of EBITDA Adjusted EBITDA
The article outlines Takeda's definition and methodology of various non-IFRS financial measures including Core Financial Measures, Free Cash Flow, and EBITDA. It emphasizes the importance of these measures for evaluating business performance while noting limitations regarding their comparability with similar metrics from other companies. Takeda plans to adjust its reporting of Free Cash Flow starting in June 2024, which may affect how investors assess its financial performance. Additionally, U.S. Dollar translations for convenience are offered, but with caution regarding their accuracy in representing financial realities.
Read more →TAKDocument FINANCIAL APPENDIX Definition of Non-IFRS Measures Definition of Core Financial Measures, Constant Exchange Rate Change, Free Cash Flow, and U.S. Dollar Convenience Translations A- 1 Definition of EBITDA Adjuste
The article outlines the definition and rationale behind several non-IFRS financial measures utilized by Takeda, including core revenue, adjusted EBITDA, and free cash flow. It provides details on how these measures help investors assess the company's financial performance and liquidity outside standard IFRS reporting. Additionally, the document highlights limitations associated with these measures, emphasizing the importance of reviewing IFRS results alongside them. Financial forecasts and currency translation considerations for investor convenience are also addressed.
Read more →TAKFINANCIAL APPENDIX Definition of Non-IFRS Measures Definition of Core Financial Measures, Constant Exchange Rate change, and Free Cash Flow A- 1 Definition of EBITDA Adjusted EBITDA and Net Debt A- 2 Reconciliations and
The article discusses Takeda's non-IFRS financial measures including definitions of core financial measures, EBITDA, adjusted EBITDA, and net debt. It also provides reconciliations and additional financial information relevant to the fiscal year 2023 first-quarter results. Measures like Free Cash Flow and the importance of constant exchange rate changes are outlined as useful tools for investors in assessing the company's liquidity and fiscal performance. Overall, the document serves as a detailed appendix to assist stakeholders in understanding Takeda's financial reporting metrics.
Read more →TAKThe following is the translation of the Articles of Incorporation of Takeda Pharmaceutical Company Limited, the latest amendment to which was made on 1st March 2023. ARTICLES OF INCORPORATION OF TAKEDA PHARMACEUTICAL COM
The article provides a detailed translation of the Articles of Incorporation for Takeda Pharmaceutical Company Limited, reflecting the latest amendments made as of March 1, 2023. It outlines the company's corporate name, location, and various business purposes, including medicine manufacturing and health services. Additionally, the document highlights the organizations within the company, such as the Board of Directors and the Audit and Supervisory Committee, as well as procedural aspects related to shareholders' meetings and voting rights. The information serves to clarify the corporate governance model of Takeda Pharmaceutical Company.
Read more →TAK(Attachment) News Release Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics With Phase 3 Study in Psoriasis Expected to Start in 2023, NDI-034858 Ha
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics With Phase 3 Study in Psoriasis Expected to Start in 2023, NDI-034858 Has the Potential to Demonstrate Best-in-class Efficacy and Safety in Psoriasis As Wel
Read more →TAK(2) Notwithstanding the provisions of the preceding paragraph, Article 14 of the Pre-amendment AOI shall remain in force with respect to a general meeting of shareholders to be held on or before the last day of February
The following is the translation of the Articles of Incorporation of Takeda Pharmaceutical Company Limited, the latest amendment to which was made on 29th June 2022. ARTICLES OF INCORPORATION OF TAKEDA PHARMACEUTICAL COMPANY LIMITED Chapter I General Provisions Article 1. (Co
Read more →TAKArticle 31. (Lapse of the Rights on Dividends) If any year-end dividends or interim dividends are not received after a lapse of three (3) full years from the date of commencement of the payment thereof, the Company shall
The following is the translation of the Articles of Incorporation of Takeda Pharmaceutical Company Limited, the latest amendment to which was made on 5th ARTICLES OF INCORPORATION OF TAKEDA PHARMACEUTICAL COMPANY LIMITED Chapter I General Provisions Article 1. (Corporate Name
Read more →TAKetokyorddayallslidesfina TAKEDA R&D INVESTOR DAY 2019 Tokyo, Japan
TAKEDA R&D INVESTOR DAY 2019 Tokyo, Japan November 21, 2019 R&D DAY AGENDA - TOKYO, NOVEMBER 21, 2019 TIME AGENDA Welcome and Introduction of Presenters 11:00 - 11:05 Ayako Iwamuro, Investor Relations, Global Finance Realizing the Potential of Plasma derived Therapies 11:05 - 11
Read more →TAKfinal_111519 Realizing the Potential of Plasma Derived Therapies Investor Relations Day, Covington, GA 15th November 2019 Julie Kim President, Plasma Derived Therapies Business Unit (PDT BU) IMPORTANT NOTICE For the purp
Realizing the Potential of Plasma Derived Therapies Investor Relations Day, Covington, GA 15th November 2019 Julie Kim President, Plasma Derived Therapies Business Unit (PDT BU) IMPORTANT NOTICE For the purposes of this notice, "presentation" means this document, any oral presen
Read more →TAKrddayallslides20191112nn TAKEDA R&D INVESTOR DAY 2019
TAKEDA R&D INVESTOR DAY 2019 NEW YORK, NY November 14, 2019 R&D DAY AGENDA - NEW YORK, NOVEMBER 14, 2019 TIME AGENDA Welcome and Opening Remarks 12:30 - 12:35 Sheelagh Cawley-Knopf, Head R&D Global Portfolio Strategy Takeda: A Global Values-Based, R&D-Driven Biopharmaceutical Le
Read more →Competitive Position
How TAK ranks across every disease it competes inCompetitive Position is a premium feature
See how TAK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial